WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018031472) PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE 6 INHIBITORS AND CD20 INHIBITORY ANTIBODIES AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/031472    International Application No.:    PCT/US2017/045751
Publication Date: 15.02.2018 International Filing Date: 07.08.2017
IPC:
A61K 39/395 (2006.01), A61K 45/06 (2006.01), A61K 31/505 (2006.01), A61P 35/00 (2006.01), A61P 35/02 (2006.01), A61P 37/00 (2006.01), A61P 37/06 (2006.01)
Applicants: ACETYLON PHARMACEUTICALS INC. [US/US]; 70 Fargo Street, Suite 205 Boston, MA 02210 (US)
Inventors: JONES, Simon, S.; (US).
MIN, Chengyin; (US).
QUAYLE, Steven, Norman; (US)
Agent: TRINQUE, Brian, C.; (US).
ALTER, Scott; (US).
BARONE, Stephen, B.; (US).
BARTON, Steven, K.; (US).
ANIS, Hissan; (US)
Priority Data:
62/372,093 08.08.2016 US
Title (EN) PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE 6 INHIBITORS AND CD20 INHIBITORY ANTIBODIES AND USES THEREOF
(FR) COMBINAISONS PHARMACEUTIQUES D'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 ET D'ANTICORPS INHIBITEUR DE CD20 ET LEURS UTILISATIONS
Abstract: front page image
(EN)The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a CD20 inhibitory antibody for use in the treatment of a B-cell disorder, such as cancer, in a subject in need thereof. Also described herein are methods for treating a B-cell disorder in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a CD20 inhibitory antibody.
(FR)La présente invention concerne des combinaisons pharmaceutiques comprenant un inhibiteur sélectif de la HDAC6 et un anticorps inhibiteur de CD20 pour le traitement de troubles des lymphocytes B comme le cancer, chez un sujet en ayant besoin. L'invention concerne également des méthodes de traitement de troubles des lymphocytes B chez un sujet en ayant besoin, comprenant l’administration au sujet d’une quantité efficace d'un inhibiteur sélectif de la HDAC6 et d’un anticorps inhibiteur de CD20.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)